Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Phase 2
Recruiting
Conditions
Ovarian Cancer
Interventions
Drug: Paclitaxel
First Posted Date
2024-05-31
Last Posted Date
2024-11-27
Lead Sponsor
Anhui Provincial Cancer Hospital
Target Recruit Count
74
Registration Number
NCT06437353
Locations
🇨🇳

Anhui Cancer Hospital, Hefei, Anhui, China

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

First Posted Date
2024-05-30
Last Posted Date
2024-07-15
Lead Sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Target Recruit Count
90
Registration Number
NCT06434610
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

🇨🇳

The First Affiliated Hospital of Bengbu Medical University, Bengbu, China

🇨🇳

XiangYa Hospital CentralSouth University, Changsha, China

and more 16 locations

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First Posted Date
2024-05-14
Last Posted Date
2024-07-30
Lead Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Target Recruit Count
235
Registration Number
NCT06412471
Locations
🇨🇳

Institute of The Hunan Cancer Hospital, Changsha, China

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

First Posted Date
2024-05-09
Last Posted Date
2024-05-09
Lead Sponsor
Tel Aviv Medical Center
Target Recruit Count
25
Registration Number
NCT06407310

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

First Posted Date
2024-05-01
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
127
Registration Number
NCT06393751

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

First Posted Date
2024-05-01
Last Posted Date
2024-08-09
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Target Recruit Count
440
Registration Number
NCT06394492
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

🇨🇳

National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

First Posted Date
2024-04-25
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
217
Registration Number
NCT06385080
Locations
🇨🇳

Changhua Christian Hospital, ChangHua, Taiwan

🇨🇳

Chang Kung Memorial Hospital, Kaohsiung City, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

and more 30 locations

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

First Posted Date
2024-04-15
Last Posted Date
2024-10-18
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
24
Registration Number
NCT06364917
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Not Applicable
Not yet recruiting
Conditions
Endometrial Neoplasms
Interventions
Drug: Tislelizumab
Drug: Paclitaxel
Drug: Carboplatin
First Posted Date
2024-04-12
Last Posted Date
2024-04-12
Lead Sponsor
Zhongnan Hospital
Target Recruit Count
20
Registration Number
NCT06363708
Locations
🇨🇳

The Central Hospital of Wuhan, Wuhan, Hubei, China

🇨🇳

Hubei maternal and child health care hospital, Wuhan, Hubei, China

🇨🇳

Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

First Posted Date
2024-04-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
450
Registration Number
NCT06356311
Locations
🇨🇳

Hunan Cancer Hospital ( Site 3014), Changsha, Hunan, China

🇨🇳

Xinjiang Medical University Cancer Hospital - Urumchi-The No.11 of Surgery building ( Site 3010), Urumchi, Xinjiang, China

🇩🇪

Städtisches Krankenhaus Kiel-2. Medizinische Klinik ( Site 1306), Kiel, Schleswig-Holstein, Germany

and more 111 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy